5-Fluorouracil is commonly used for gastrointestinal cancer treatment in an adjuvant setting; however, the toxicity can lead to a reduction, delay, or discontinuation of treatment. We retrospectively investigated the association between the 5-fluorouracil degradation rate (5-FUDR) and genetic polymorphisms of TSER, DPYD, and MHTFR with toxicity in colorectal cancer patients treated with adjuvant FOLFOX. Pretreatment 5-FUDR and MTHFR A1298T or C677T, TSER, and DPYD gene polymorphisms were characterized in stages II-III colorectal cancer patients. Patients were classified into three metabolic classes according to the 5-FUDR value. Association with toxicities was evaluated retrospectively using logistic regression analysis. Overall, 126 patients were selected (35 women, 91 men). Seven patients were poor metabolizers, 116 patients were normal metabolizers and three patients were ultra-rapid metabolizers. The median 5-FUDR was 1.53 ng/ml/10 6 cells/min (range: 0.42-2.57 ng/ml/10 6 cells/min). Severe, rate-limiting toxicities (grades 3-4) were encountered in 22.2% of patients. No associations between MTHFR or TSER polymorphisms and toxicity were detected, whereas 5-FUDR showed a statistically significant association with toxicity (P = 0.0047). The DPYD heterozygous mutation was detected in only one patient, who showed grade 4 hematological toxicity and a lower 5-FUDR value. The 5-FUDR value seems not to be affected by MTHFR and TSER polymorphisms. Compared with the available pharmacogenomics tests, the pretreatment evaluation of 5-FUDR increases the proportion of identified colorectal patients at high risk for severe toxicity. Thus, it appears to be a suitable pretreatment toxicity biomarker in a subgroup of patients in whom dose-intensity maintenance is the key factor. Anti-Cancer Drugs 28:322-326
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Introduction 5-Fluorouracil (5-FU) is an anticancer drug belonging to the family of antimetabolites used for gastrointestinal cancer treatment, both in the adjuvant and in the metastatic setting. Inside the cells, 5-FU is transformed into active metabolites through a phosphorylation process for about 1-3% and into inactive metabolites for about 80-85% [1] (Fig. 1) .
The enzyme responsible for the catabolism process is the dihydropyrimidine dehydrogenase (DPD), which can transform the 5-FU into 5,6-dihydro-5-fluorouracil [1] . Genetic variants in the DPD encoding gene (DPYD) have emerged as predictive risk markers for 5-FU-associated toxicities [2] [3] [4] [5] [6] [7] [8] . In a recently published study by Kuilenburg et al. [9] , 34 single nucleotide polymorphisms (SNPs) were detected in the DPYD gene, 15 of which were associated with altered fluoropyrimidine plasma concentrations. Moreover, the splice variant IVS14 + 1G > A (rs3918290; known as the *2A allele) seems to be associated with an increased risk of grades 3-4 (G3-4) toxicities [3, 5, 8] . In a recent study including more than 2000 patients, carried out by Deneen et al. [7] , patients carrying the DPYD*2A polymorphic allele were treated with a 50% reduced dose of fluoropyrimidine, showing a 45% reduction in severe toxicity. Unfortunately, the authors did not present outcome data. Moreover, considering the low frequency of DPD deficiency in the general population [10] , the detection of DPYD genetic polymorphisms could lead to the pre-emptive identification of only a small fraction of patients at risk of developing severe toxicities.
A lower amount of 5-FU is transformed into two active metabolites: fluorodeoxyuridine monophosphate and fluorouridine monophosphate [1] . (Fig. 1) . These two metabolites cause DNA and RNA damage, respectively. First, fluorodeoxyuridine monophosphate forms an inactive ternary complex with thymidylate synthase and N-5-10-methylenetetrahydrofolate, inhibiting thymidylate synthesis and consequent DNA transcription impairement (http://www.drugbank.ca/drugs/DB01101).
Furthermore, the second active metabolite fluorouridine monophosphate, phosphorylated into fluorouridine triphosphate, leads to RNA synthesis injury when incorporated instead of uridine triphosphate (http://www.drugbank.ca/drugs/ DB01101).
The most studied polymorphisms are two SNPs in the methylenetetrahydrofolate reductase gene (MTHFR), C677T and A1298T, and a variable number tandem repeat in the thymidylate synthase enhancer region (TSER), even though their clinical usefulness is actually controversial [11] [12] [13] [14] . In fact, polymorphisms in a single gene cannot reflect the entire drug's metabolism, which is the result of actions of multiple enzymes, including transporters [15, 16] .
5-FUDR is a phenotypic test that could represent the whole 5-FUDR metabolism as it indicates the amount drug consumed in a time unit. We previously developed a liquid chromatography-tandem mass spectrometry method to measure in vitro the decrease in a fixed amount of 5-FU after 2 h of incubation with peripheral blood mononuclear cells [17] . 5-FUDR shows a normal distribution in a population of 1010 cancer patients and three metabolic classes were identified according to the fifth and the 95th centile: poor metabolizers (PM) (5-FUDR ≤ 0.85 ng/ml/10 6 cells/min); normal metabolizers (NM) (0.85 ng/ml/106 cells/ min < 5-FUDR > 2.2 ng/ml/10 6 cells/min); and ultra-rapid metabolizers (UM) (5-FUDR ≥ 2.2 ng/ml/10 6 cells/min). In particular, we analyzed a cohort of colorectal cancer patients, showing an increased risk of developing severe toxicity in the PM and UM group [18] . Moreover, in another study, we found an association between four DPYD SNPs and reduction of 5-FUDR, with the splice variant IVS14 + 1G > A causing the larger decrease [19] .
In this retrospective study, we investigated the association between 5-FUDR, polymorphisms in DPYD, MTHFR, TSER, and toxicity in a cohort of colorectal cancer patients treated with adjuvant FOLFOX. The aim of this work is to early identify patients at high risk of developing G3-4 toxicities. In fact, severe toxicities are most commonly responsible for dose reduction, delay of administration, therapy discontinuation and consequent loss of dose intensity. We analyzed a subgroup of patients undergoing adjuvant treatment and were therefore candidates for healing, in whom preserving dose intensity is of primary importance.
Patients and methods

Patients' selection
Patients with a histological diagnosis of colorectal cancer, who had undergone adjuvant FOLFOX at Sant'Andrea Hospital of Rome during the period 2009-2012, were retrospectively studied.
The inclusion criteria were: patients with a histological diagnosis of stages II-III colorectal cancer; patients who Exclusion criteria were: patients affected by metastatic colorectal cancer; relevant diseases within 6 months (i.e. myocardial infarction, lung fibrosis, etc.), and those who had received 5-FU-based chemotherapy in the past.
Chemotherapy was administered every 2 weeks for 6 months (12 administrations for each patient) [20] .
Toxicities were assessed at day 1 of each administration and were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Event, version 3 (CTCAE 3.0) [21] .
The study was carried out in accordance with the Declaration of Helsinki and the protocol was approved by the institutional ethic committee.
Genotyping
At our Institution, we use the 5-FUDR assay and DPYD, TSER, MTHFR C677T, and A1298C polymorphisms as routine pretreatment tests, providing information on possible toxicities and enabling careful monitoring of patient carrying alteration.
Each patient was subjected to venous blood sampling, prescribed by the clinician. Genomic DNA was isolated using the X-tractor Gene system (Corbett Life Science, Sydney, New South Wales, Australia) to analyze germinal polymorphisms. The commercial kit 'Fluoropyrimidine Response' (Diatech, Jesi, Italy), based on real-time PCR technology, was used to analyze the IVS14 + 1G > A polymorphism in the DPYD gene, and C677T and A1298C SNPs in the MTHFR gene. Subsequently, the amplified DNA regions were sequenced using the Pyrosequencer PyroMark ID system (Biotage AB and Biosystems, Uppsala, Sweden). Also, variable numbers of tandem repeats in the TSER were detected using PCR ('Fluoropyrimidine Response'; Diatech) and visualized on a 2.2% agarose gel.
5-Fluorouracil degradation rate determination
The assay for 5-FUDR was performed using a 5-FUDR assay kit (Eureka srl-Lab Division, Chiravalle, Ancona, Italy) with an HPLC-MS/MS instrument, including an Agilent 1100 chromatographic system coupled to an API 3200 triple quadrupole (ABSCIEX, Framingham, MA, USA). Freshly prepared peripheral blood mononuclear cells (2.5-3.5 × 10 6 cells) were incubated at 37°C with a known amount of 5-FU with shaking. Cells were lysed and centrifuged at 0, 1, and 2 h. 5-FU concentration in the supernatants was quantified by HPLC-MS/MS. 5-FUDR is expressed as ng 5-FU/ml/10 6 cells/min [17] . Patients were classified into three metabolic classes, according to the values of the fifth and 95th centile of the normal distribution of 5-FUDR, as we reported previously: PM (i.e. ≤ fifth centile, ≤ 0.85 ng/ml/10 6 cells/min); NM (i.e. > fifth centile and < 95th centile, > 0.85 ng/ml/10 6 cells/ min and < 2.2 ng/ml/10 6 cells/min); and UM (i.e. ≥ 95th centile, ≥ 2.2 ng/ml/10 6 cells/min) [18] .
Statistical analysis
Statistical analyses were carried out using MedCalc for Windows, version 10.2.0.0 (MedCalc Software, MariaKerke, Belgium).
One-way analysis of variance test was used to study correlations between 5-FUDR and toxicity, whereas the χ 2 -test and the Pearson correlation coefficient were used to determine the association between 5-FUDR and gene polymorphisms. Odds ratio and 95% confidence intervals were reported on the basis of univariate and multivariate logistic regression models.
Statistical significance was conventionally defined as P of 0.05 or less.
Results
We enrolled 126 patients (35 women and 91 men, median age: 65 years, range: 33-86 years) with stages II-III colorectal cancer. All selected patients had undergone colectomy, followed by adjuvant FOLFOX every 2 weeks for 6 months. Genetic tests for DPYD, TSER, and MTHFR polymorphisms and 5-FUDR pretreatment assay were available for each patient, as reported in Table 1 . The median 5-FUDR in the overall population was 1.53 ng/ml/10 6 cells/min (range: 0.42-2.57 ng/ml/10 6 cells/min). Patients were classified into three metabolic classes as reported previously: seven patients were PM, 116 patients were NM, and three patients were UM.
Severe rate-limiting toxicities (CTCAE G3-4) were encountered in 22.2% of the overall population (28 patients) and were hematological in 13.5% of the cases, gastrointestinal in 7.1%, neurological in 1.6%, cutaneous in 0.8%, and cardiac in 0.8% (Table 2) .
No association was detected between toxicity and TSER, MTHFR C677T, or MTHFR A1298C polymorphisms in a univariate analysis. The only patients carrying a heterozygous mutation in the DPYD gene showed G4 hematological toxicity, but the sample size was insufficient to reach conclusive results. In contrast, a statistically significant association was detected (P = 0.0047) between abnormal 5-FUDR value and G3-4 toxicities, present, respectively, in 71.4% of the cases in the PM group and 33.3% of the cases in the UM group versus 19% of the cases in the NM group (Table 1) . Moreover, 71.4% of the patients in the PM group and 66.7% of the patients in the UM group received a reduced chemotherapy dose because of adverse events versus 31% in the NM group.
In a multivariate analysis, no associations were identified between toxicity and sex, age, TSER, MTHFR C677T, or MTHFR A1298C polymorphisms, whereas 5-FUDR appeared to be associated significantly with G3-4 toxicities (odds ratio = 0.2944, 95% confidence interval: 0.0890-0.9743, P = 0.0452) (Table 3) .
Moreover, 5-FUDR was not associated with TSER (P = 0.704), MTHFR C677T (P = 0.654), and MTHFR A1298C (P = 0.674) in our patient cohort. The only patients carrying the SNP variant in the DPYD gene showed the lower value of the entire population in the 5-FUDR (0.42 ng/ml/10 6 cells/min). Unfortunately, the exiguous sample size did not allow us to identify a direct association between the DPYD polymorphism and 5-FUDR.
Discussion
Despite the benefits of fluoropyrimidine treatment in adjuvant setting [20, [22] [23] [24] , the development of severe toxicities leads to dose reduction, delay in administration, and discontinuation of therapy. Considering the setting of resected patients, dose-intensity maintenance should be considered an important factor. In fact, previous studies showed that chemotherapy duration and intensity have been associated with survival [25] [26] [27] [28] . In particular, two studies analyzing patients treated with adjuvant 5-FU and oral capecitabine showed that patients receiving a relative dose intensity of more than 70% had improved diseasefree survival and overall survival [25, 26] . Similarly, failure to complete adjuvant treatment seems to be associated with a worse outcome [27, 28] .
Although several pharmacogenetic studies have been carried out to date to identify patients at risk of developing toxicity, a predictive marker has not yet been identified. Actually, the more reliable data are available for the DPYD polymorphisms [2] [3] [4] [5] [6] [7] [8] , but the low frequency of DPD deficiency could lead to identify only a small fraction of patients at risk of developing toxicity. Thus, we studied a phenotypic factor able to identify a larger fraction of patients and to reflect the entire 5-FU metabolism.
We found that patients with a slower 5-FU metabolism (called PM group) showed more frequently dose-limiting toxicities. This is probably because of a decreased 5-FU clearance, as suggested by the association between 5-FUDR and SNPs in the DPYD gene [19] . Interestingly, we also identified an association between severe toxicities and rapid 5-FU metabolism (UM group). Rapid metabolism could be related to a fast degradation by DPD or a fast transformation into active metabolites. In the first case, we can ascribe the development of toxicity to the presence of an increased amount of inactive metabolites. In the second case, toxicity can be due to a higher amount of active metabolites in plasma and modifications in activating enzyme levels could be responsible [29] [30] [31] . In both the cases, we should expect a different impact on outcome, and patients with slower metabolism could present a different prognosis. Moreover, we do not believe that the reported data are influenced by oxaliplatin treatment. In fact, it is widely known that the gene variants studied do not affect the metabolic pathways of this drug in any way. 
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Overall, in this study, we found that 21.4% of the patients who developed G3-4 toxicity (six/28 patients) had altered 5-FUDR. These two classes include by definition 10% of the overall population (< fifth and > 95th centile). Thus, 5-FUDR could potentially help identify a larger fraction of patients at risk of developing severe toxicity than the available pharmacogenomics tests. Moreover, considering the low cost, the quickly available results, and the noninvasive sampling method of the pretreatment 5-FUDR assay, it appears to be a suitable pretreatment toxicity biomarker.
Despite the promising data reported in this paper, further prospective and larger studies are necessary to confirm these results. Prognostic evaluation and pharmacokinetics analysis, measuring plasmatic fluorouracil metabolites, could help to better understand the significance of 5-FUDR alteration.
